The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...

ATLANTA -- Scenarios for patent foramen ovale (PFO) closure not covered by the pivotal trials were a key subject of guidelines released by the Society for Cardiovascular Angiography and Interventions ...

W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

Percutaneous closure of patent foramen ovale (PFO) is a widely used procedure, but the long-term safety and efficacy of the technique have not been investigated. This prospective, observational, ...

Patients with migraine, patent foramen ovale (PFO), and atrial septal aneurysm (ASA) have more frequent ischemic brain lesions, migraine with aura, and larger PFO sizes than patients with migraines ...